Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
MI to Weigh Ban on Stock Buybacks for Companies Receiving Tax Breaks Michigan Sen. Mallory McMorrow (D) introduced a bill ( SB 783 ) that would prohibit publicly traded companies receiving economic incentives...
VA House Passes Paid Sick Leave Bill Virginia’s House of Delegates approved a bill ( HB 5 ) that would expand the state’s current paid sick leave law, which applies only to a small segment...
VA Lawmakers Okay Prescription Drug Affordability Board Virginia lawmakers have passed legislation ( SB 271 / HB 483 ) that would create a prescription drug affordability board to review drug prices...
Geolocation data has become a new frontier in privacy protection. This year, Virginia could join Maryland and Oregon as the first states to prohibit the sale of information that provides the precise...
Insurance Bill Raises Concerns in FL A fast-moving bill ( SB 1028 ) in Florida, sponsored by Sen. Joe Gruters (R), chairman of the Senate’s Banking and Insurance Committee, would require Citizens...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
Virginia lawmakers have passed legislation (SB 271/HB 483) that would create a prescription drug affordability board to review drug prices and set limits on how much state-regulated health plans can pay for drugs. The legislation is similar to that enacted in other states, but Virginia’s would be the first linking the board’s activity to drug price negotiations between manufacturers and Medicare mandated by the federal Inflation Reduction Act of 2022. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
After decades of debating whether to restrict direct-to-consumer drug advertising, the Trump administration and federal lawmakers appear to be moving in that direction.
Last February, U.S. Sen. Angus King (I-ME) introduced a bill (SB 483) prohibiting drugs from being advertised directly to consumers for three years after they receive FDA approval. The measure is still pending.
In September President Trump issued a presidential memorandum calling for the reversal of a 1997 policy change that allowed drug advertising on television. On the same day, the FDA announced that it was “sending thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads.” (NEW YORK TIMES)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.